Incidence of submacular haemorrhage (SMH) in Scotland: a Scottish Ophthalmic Surveillance Unit (SOSU) study

被引:9
作者
Al-Hity, Aws [1 ]
Steel, David H. [1 ]
Yorston, David [2 ,3 ]
Gilmour, David [1 ]
Koshy, Zachariah [4 ]
Young, David [5 ]
Hillenkamp, Jost [6 ]
McGowan, Gerard [1 ]
机构
[1] Gartnavel Royal Hosp, Tennent Inst Ophthalmol, 1053 Great Western Rd, Glasgow G12 0YN, Lanark, Scotland
[2] Sunderland Eye Infirm, Sunderland, England
[3] Newcastle Univ, Inst Genet Med, Newcastle, NSW, Australia
[4] Univ Hosp Ayr, Ayr, Scotland
[5] Univ Strathclyde, Dept Math & Stat, Glasgow, Lanark, Scotland
[6] Univ Kiel, Kiel, Germany
关键词
TISSUE-PLASMINOGEN ACTIVATOR; CHOROIDAL NEOVASCULAR LESIONS; ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; INTRAVITREAL; RANIBIZUMAB; SECONDARY; ENDOPHTHALMITIS; EPIDEMIOLOGY; VITRECTOMY;
D O I
10.1038/s41433-018-0239-4
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose Submacular haemorrhage (SMH) is a cause of severe visual loss in neovascular age-related macular degeneration (nAMD). The incidence is uncertain and furthermore there is no widely used classification system nor agreed best practice. The aim of this national surveillance study was to identify the incidence, presenting features and clinical course of new fovea-involving submacular haemorrhage associated with nAMD. Methods A questionnaire was sent monthly to every ophthalmic specialist in Scotland over a 12-month period asking them to report all newly presenting patients with acute SMH secondary to nAMD of at least two disc diameters (DDs) in greatest linear diameter. A follow-up questionnaire was sent 6 months after initial presentation. Cases related to other causes were excluded. Results Twenty-nine cases were reported giving an incidence of 5.4 per million per annum (range 2-15). The mean age was 83 years (range 66-96) and females accounted for 17/29 (59%). Fifteen of the 29 cases (52%) had a past history of AMD, of which 7 had nAMD. Nineteen of the 29 cases (66%) presented within 7 days of onset and the majority had SMH of < 11 DD (20/29, 69%). Treatment options comprised the following: observation (n = 6, 21%), anti-VEGF alone (n = 6, 21%) or vitrectomy with co-application of tissue plasminogen activator (TPA), anti-VEGF and gas (n = 17, 58%). The vitrectomy group experienced the greatest change in vision from logMAR 1.89-1.50 (p = 0.374). Four of 20 (20%) cases with 6 months follow-up suffered a re-bleed at a mean time of 96 days. Conclusions The incidence, clinical features and course of a consecutive national cohort of patients with SMH secondary to nAMD are presented.
引用
收藏
页码:486 / 491
页数:6
相关论文
共 26 条
[1]   Purtscher's retinopathy: epidemiology, clinical features and outcome [J].
Agrawal, Ashish ;
McKibbin, Martin .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2007, 91 (11) :1456-1459
[2]  
Bopp S, 2012, OPHTHALMOLOGE, V109, P635, DOI 10.1007/s00347-012-2563-6
[3]   Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: Ophthalmic findings - SST report no. 13 [J].
Bressler, NM ;
Bressler, SB ;
Childs, AL ;
Haller, JA ;
Hawkins, BS ;
Lewis, H ;
MacCumber, MW ;
Marsh, MJ ;
Redford, M ;
Sternberg, P ;
Thomas, MA ;
Williams, GA .
OPHTHALMOLOGY, 2004, 111 (11) :1993-2006
[4]   PROSPECTIVE ONE-YEAR STUDY OF RANIBIZUMAB FOR PREDOMINANTLY HEMORRHAGIC CHOROIDAL NEOVASCULAR LESIONS IN AGE-RELATED MACULAR DEGENERATION [J].
Chang, Margaret A. ;
Do, Diana V. ;
Bressler, Susan B. ;
Cassard, Sandra D. ;
Gower, Emily W. ;
Bressler, Neil M. .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2010, 30 (08) :1171-1176
[5]   INTRAVITREAL VERSUS SUBRETINAL ADMINISTRATION OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR COMBINED WITH GAS FOR ACUTE SUBMACULAR HEMORRHAGES DUE TO AGE-RELATED MACULAR DEGENERATION An Exploratory Prospective Study [J].
De Jong, Jan H. ;
Van Zeeburg, Elsbeth J. T. ;
Cereda, Matteo G. ;
Van Velthoven, Mirjam E. J. ;
Faridpooya, Koorosh ;
Vermeer, Koenraad A. ;
Van Meurs, Jan C. .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2016, 36 (05) :914-925
[6]   Incidence of cases sf ocular trauma admitted to hospital and incidence of blinding outcome [J].
Desai, P ;
MacEwen, CJ ;
Baines, P ;
Minassian, DC .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1996, 80 (07) :592-596
[7]   The British Ophthalmological Surveillance Unit: an evaluation of the first 3 years [J].
Foot, B ;
Stanford, M ;
Rahi, J ;
Thompson, J .
EYE, 2003, 17 (01) :9-15
[8]   Vitrectomy with subretinal tissue plasminogen activator and ranibizumab for submacular haemorrhages secondary to age-related macular degeneration: retrospective case series of 45 consecutive cases [J].
Gonzalez-Lopez, J. J. ;
McGowan, G. ;
Chapman, E. ;
Yorston, D. .
EYE, 2016, 30 (07) :929-935
[9]   Management of submacular hemorrhage with intravitreal versus subretinal injection of recombinant tissue plasminogen activator [J].
Hillenkamp, Jost ;
Surguch, Vladimir ;
Framme, Carsten ;
Gabel, Veit-Peter ;
Sachs, Helmut G. .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2010, 248 (01) :5-11
[10]   INTRAVITREAL RANIBIZUMAB FOR CHOROIDAL NEOVASCULARIZATION WITH LARGE SUBMACULAR HEMORRHAGE IN AGE-RELATED MACULAR DEGENERATION [J].
Iacono, Pierluigi ;
Parodi, Maurizio B. ;
Introini, Ugo ;
La Spina, Carlo ;
Varano, Monica ;
Bandello, Francesco .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2014, 34 (02) :281-287